Purpose: Evaluate the clinical presentation and imaging findings of breast implantassociated anaplastic large cell lymphoma (BIA ALCL) at a large US cancer center.
10 years (range: [6] [7] [8] [9] [10] [11] [12] [13] [14] . BIA ALCL was identified in patients with saline (4/11) and silicone (5/11) implants. Implants were textured in 7/11 (63%) and unknown in 4/11 (36%) cases. All patients presented with a peri-implant seroma, (9/11 documented on imaging). Two of 11 patients had a mass within this seroma. Ten of 11 patients (91%) presented with symptoms.
Conclusions:
Saline and silicone breast implants may predispose patients to a rare lymphoma subtype, BIA ALCL, which presents on imaging as a peri-implant fluid collection ± mass.
| INTRODUCTION
Anaplastic lymphoma kinase negative (ALK−) anaplastic large cell lymphoma (ALCL) accounts for only 2%-3% of T cell and natural killer-cell lymphomas.
1 Recently, interest in ALCL has increased as new studies have reported links between breast implants and ALK-ALCL. Keech and Creech first recognized this association in 1997. 2 Since then, two large population studies 3,4 and many case reports have confirmed cases of ALCL arising as peri-implant seromas with and without an associated mass [5] [6] [7] [8] [9] ; these cases have been referred to as breast implant-associated (BIA) ALCL. BIA ALCL was recognized by the World Health Organization as a distinct ALCL subtype and more recently recognized by the US Food and Drug Administration. 10, 11 Currently, there are no guidelines for screening for BIA ALCL;
meanwhile, the management of BIA ALCL has been based on guidelines for ALK-ALCL. When BIA ALCL is confined to the implant capsule, disease is almost always localized, often has an indolent growth rate, and surgical treatment alone is usually recommended with implant removal and capsulectomy. There are rare cases with dissemination beyond the peri-implant fluid and capsule. 10, 11 For these cases, the behavior and prognosis appear similar to systemic ALK-ALCL and they are treated accordingly. [12] [13] [14] 
| Imaging characteristics
Imaging modalities included ultrasound, MRI, and PET. Imaging was available for nine of 11 (82%) patients; 78% (7/9) of patients were found to have a seroma without an associated mass, while 22% (2/9) of patients had a seroma with an associated mass. Representative BIA ALCL cases on imaging and pathology are shown in Figures 1-4 .
Peri-implant fluid collections were identified unilaterally in the | 71 diseased breast of all (11/11, 100%) patients at pathology, of whom 10/11 (91%) had bilateral breast implants, as was noted above.
All patients were treated with capsulectomy and implant removal. Two patients (cases 1 and 4) had axillary adenopathy and were also treated with cyclophosphamide, doxorubicin, etoposide, vincristine, and prednisone (CHOEP) chemotherapy regimen. For case 1, no imaging was available but adenopathy was reported in the clinical chart and on pathology, with the nodal biopsy specimen available; case 4 had a mass on imaging associated with the peri-implant seroma (Figures 3 and 4) . Case 6 underwent chemotherapy for synchronous stage IV right invasive lobular breast cancer.
| DISCUSSION
Here we present the clinical and imaging characteristics of 11 cases of BIA ALCL, a rare lymphoma subtype, diagnosed on fine needle aspiration of a seroma, core biopsy of a mass, or at capsulectomy.
Presenting symptoms were often nonspecific and most commonly included breast swelling/erythema, or mass. Peri-implant seromas ± mass were detected on a range of imaging modalities, including mammography, ultrasound, MRI, and PET-CT. BIA ALCL was identified in patients with and without history of breast cancer and was associated with saline and with silicone implants, similar to prior studies.
2,7
While our study could only include a few patients diagnosed with BIA ALCL due to its low incidence, our findings support prior Staining for CD30 should be expressed in all cells and is usually concentrated at the membrane and Golgi area (Figures 2 and 4) . Strong CD30 expression is essential for this diagnosis and may aid in distinguishing from other peripheral T cell lymphomas. Anaplastic cells also commonly express cytotoxic-associated markers, such as T cell intercellular antigen 1 (TIA-1) and granzyme-B, with a minority of cases expressing epithelial membrane antigen (EMA). 16 In cases lacking expression of lineage specific markers, that is, those having a "null"
cell phenotype, T cell receptor gene rearrangement studies may be of value.
While both smooth and textured breast implants are commonly used, in our study all cases of BIA ALCL with known implant type were associated with textured implants. Given the small number of cases at our institution, we are unable to establish a correlation between textured over smooth breast implants, although several case reports have similarly reported BIA ALCL in textured breast 
